Two major studies from a significant clinical trial involving over 17,000 adults report that semaglutide effectively reduces weight and waist circumference across diverse demographics over four years. The medication not only offers sustained weight loss but also presents cardiovascular benefits irrespective of the initial weight or the extent of weight reduction.
Importantly, the findings also indicate that semaglutide delivers cardiovascular benefits irrespective of starting weight and the amount of weight lost—suggesting that even patients with mild obesity or those not losing weight are likely to gain some advantage. The researchers examined markers of obesity that include body composition and fat distribution , rather than just BMI alone, to help clarify the effect of semaglutide on central abdominal fat which has been proven to cause greater cardiovascular risk than general obesity.
Similarly, in the semaglutide group, average WHtR fell by 6.9% compared with 1% in the placebo group.